Recombinant BCG as a vaccine vehicle to protect against tuberculosis

Triccas, James A.

doi:10.4161/bbug.1.2.10483

Cited by 12 publications

(8 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many studies have focused on the use of rBCG as a means of increasing the protection against TB ( 28 , 29 ). Recombinant BCG expressing important M. tuberculosis antigens, such as Ag85A, have been shown to induce better immune responses than those elicited by standard BCG in animal models and, as a consequence, these strains are under evaluation in clinical trials ( 30 ).…”

Section: Recombinant Vaccine Strategiesmentioning

confidence: 99%

Recombinant vaccines and the development of new vaccine strategies

Nascimento

Leite

2012

Braz J Med Biol Res

310

192

View full text Add to dashboard Cite

Vaccines were initially developed on an empirical basis, relying mostly on attenuation or inactivation of pathogens. Advances in immunology, molecular biology, biochemistry, genomics, and proteomics have added new perspectives to the vaccinology field. The use of recombinant proteins allows the targeting of immune responses focused against few protective antigens. There are a variety of expression systems with different advantages, allowing the production of large quantities of proteins depending on the required characteristics. Live recombinant bacteria or viral vectors effectively stimulate the immune system as in natural infections and have intrinsic adjuvant properties. DNA vaccines, which consist of non-replicating plasmids, can induce strong long-term cellular immune responses. Prime-boost strategies combine different antigen delivery systems to broaden the immune response. In general, all of these strategies have shown advantages and disadvantages, and their use will depend on the knowledge of the mechanisms of infection of the target pathogen and of the immune response required for protection. In this review, we discuss some of the major breakthroughs that have been achieved using recombinant vaccine technologies, as well as new approaches and strategies for vaccine development, including potential shortcomings and risks.

show abstract

Section: Recombinant Vaccine Strategiesmentioning

confidence: 99%

Recombinant vaccines and the development of new vaccine strategies

Nascimento

Leite

2012

Braz J Med Biol Res

310

192

View full text Add to dashboard Cite

show abstract

“…Various systems are used for delivering antigens as subunit vaccines to human and animal organisms, including recombinant viral vectors [ 16 ], recombinant bacterial systems [ 17 ], and lipoglycans conjugated with proteins [ 18 ]. Oral administration within plant cells [ 7 , 19 , 20 ] is among the promising systems.…”

Section: Introductionmentioning

confidence: 99%

Transgenic Carrot Expressing Fusion Protein ComprisingM. tuberculosisAntigens Induces Immune Response in Mice

Permyakova

Zagorskaya

Belavin

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Tuberculosis remains one of the major infectious diseases, which continues to pose a major global health problem. Transgenic plants may serve as bioreactors to produce heterologous proteins including antibodies, antigens, and hormones. In the present study, a genetic construct has been designed that comprises the Mycobacterium tuberculosis genes cfp10, esat6 and dIFN gene, which encode deltaferon, a recombinant analog of the human γ-interferon designed for expression in plant tissues. This construct was transferred to the carrot (Daucus carota L.) genome by Agrobacterium-mediated transformation. This study demonstrates that the fusion protein CFP10-ESAT6-dIFN is synthesized in the transgenic carrot storage roots. The protein is able to induce both humoral and cell-mediated immune responses in laboratory animals (mice) when administered either orally or by injection. It should be emphasized that M. tuberculosis antigens contained in the fusion protein have no cytotoxic effect on peripheral blood mononuclear cells.

show abstract

“…Efficient and affordable vaccination approaches should rely on low‐cost production systems with facile delivery, which will significantly facilitate massive immunization in limited recourse settings, where the vaccine is urgently required (Rosales‐Mendoza et al ., ). Different systems have been used for delivery of subunit vaccines including recombinant bacterial vector system (Triccas, ), recombinant viral vector system (Sereinig et al ., ) and lipoglycan–protein conjugate system (Hamasur et al ., ). However, the high cost of these systems, as well as concerns related to patient safety particularly in terms of bacterial (Yurina, ) and viral vectors, promoted plant‐based delivery system approach.…”

Section: Plant Molecular Pharming Related To Hiv and Tbmentioning

confidence: 99%

The potential of plant systems to break the HIV‐TB link

Habibi

Daniell

Soccol

et al. 2019

Plant Biotechnology Journal

View full text Add to dashboard Cite

Summary Tuberculosis (TB) and human immunodeficiency virus (HIV) can place a major burden on healthcare systems and constitute the main challenges of diagnostic and therapeutic programmes. Infection with HIV is the most common cause of Mycobacterium tuberculosis (Mtb), which can accelerate the risk of latent TB reactivation by 20‐fold. Similarly, TB is considered the most relevant factor predisposing individuals to HIV infection. Thus, both pathogens can augment one another in a synergetic manner, accelerating the failure of immunological functions and resulting in subsequent death in the absence of treatment. Synergistic approaches involving the treatment of HIV as a tool to combat TB and vice versa are thus required in regions with a high burden of HIV and TB infection. In this context, plant systems are considered a promising approach for combatting HIV and TB in a resource‐limited setting because plant‐made drugs can be produced efficiently and inexpensively in developing countries and could be shared by the available agricultural infrastructure without the expensive requirement needed for cold chain storage and transportation. Moreover, the use of natural products from medicinal plants can eliminate the concerns associated with antiretroviral therapy (ART) and anti‐TB therapy (ATT), including drug interactions, drug‐related toxicity and multidrug resistance. In this review, we highlight the potential of plant system as a promising approach for the production of relevant pharmaceuticals for HIV and TB treatment. However, in the cases of HIV and TB, none of the plant‐made pharmaceuticals have been approved for clinical use. Limitations in reaching these goals are discussed.

show abstract

Recombinant BCG as a vaccine vehicle to protect against tuberculosis

Abstract: Recombinant BCG as a vaccine vehicle to protect against tuberculosis

Cited by 12 publications

References 75 publications

Recombinant vaccines and the development of new vaccine strategies

Recombinant vaccines and the development of new vaccine strategies

Transgenic Carrot Expressing Fusion Protein ComprisingM. tuberculosisAntigens Induces Immune Response in Mice

The potential of plant systems to break the HIV‐TB link

Contact Info

Product

Resources

About